A basic approach to CKD  by Simon, Eric E. & Lee Hamm, L.
 commentar y 
Kidney International (2010) 77    567
 Metabolic acidosis commonly complicates 
chronic kidney disease (CKD) and has 
adverse eff ects on bone, nutrition, and 
metabolism. For patients treated with 
dialysis, the National Kidney Foundation 
Kidney Disease Outcomes Quality Initia-
tive (KDOQI) guidelines recommend 
maintaining serum bicarbonate 
levels     22  m M to help prevent these 
complications. 1 Phisitkul  et al. 2 (this 
issue) now demonstrate that sodium 
citrate (as an alkalinizing agent) may 
ameliorate kidney injury in CKD 
patients not on dialysis. Further, they 
provide evidence in humans that bicar-
bonate lowers urinary endothelin levels, 
and hence increased endothelin may be 
part of the mechanism whereby acidosis 
hastens CKD progression. 
 Metabolic acidosis is a predictable 
accompaniment of CKD. 3 Adaptations 
in kidney acid excretion may initially 
prevent a fall in serum bicarbonate 
levels, but as glomerular fi ltration rate 
(GFR) declines to the 20- to 40-ml / min 
range, metabolic acidosis commonly 
develops. Initially this acidosis is typi-
cally a hyperchloremic variety, but in 
later stages of CKD it may be a high-
anion-gap acidosis. Hydrogen ion excre-
tion is relatively intact, so urine pH 
generally remains appropriately low. 
When factored for GFR,  titratable acid 
excretion is augmented. However, the 
ability to excrete more phosphate during 
acidosis is limited, so adaptation in titrat-
able acidic excretion is limited. As in all 
metabolic acidoses, the major adaptation 
to net urinary acid excretion is an increase 
in ammonium excretion. In metabolic 
acidosis, ammonium excretion may 
increase manyfold; in CKD, when factored 
for GFR, ammonium excretion is aug-
mented. However, even when factored for 
GFR, ammonium excretion in CKD is 
lower than is seen in metabolic acidosis of 
other etiologies. In absolute terms, total 
urinary ammonium excretion is markedly 
impaired. Several mechanisms contribute 
to the failure of ammonium excretion to 
keep pace with the decline in GFR. Proxi-
mal tubule ammoniagenesis is increased 
but may be insufficient because of a 
decline in total nephron mass and possi-
bly because of a defect in glutamine uptake 
(the major source of renal ammonium). 
Furthermore, ammonium produced in 
the proximal tubule may not be trans-
ported into the collecting duct, predom-
inantly because of a decrease in 
interstitial ammonium concentration 
(see below). Whether other mechanisms 
exist to limit ammonium excretion is 
unknown, but some data suggest that 
the specifi c ammonia transporter Rhcg 
does increase in the 5 / 6 nephrectomy 
model of reduced renal mass. 4 
 A few previous studies have suggested 
that alkali therapy slows progression of 
CKD. In 1985, Nath  et al. reported that 
correction of metabolic acidosis in the rat 
remnant kidney model ameliorates the 
decline in renal function. 5 Tubulointer-
stitial injury is a powerful predictor of 
progression in kidney failure, and the 
study by Nath  et al. showed that bicarbo-
nate treatment led to less severe intersti-
tial injury and higher GFRs. Nath  et al. 
presented data in support of the postulation 
that increased ammonia levels in the kidney 
led to increased complement cleavage, 
which in turn mediated tubulointerstitial 
injury. Although complement cleavage 
may well play an important role in pro-
gression of kidney failure, it was not con-
vincingly shown to be paramount. 
Notably, in the same rat remnant kidney 
model, ammonia levels in the cortex are 
about twice those of controls, but levels 
in the medulla are actually lower. 6 Also, 
some subsequent experimental studies 
failed to support the benefi cial eff ects of 
alkali on progression of renal disease. 
 In more recent years, our understand-
ing of the mechanisms of progression of 
CKD has markedly expanded. However, 
few laboratories have addressed how 
bicarbonate might ameliorate CKD 
progression. But Wesson ’ s group has 
explored the effects of acidosis on 
endothelin and the subsequent effects 
on kidney injury. 7 – 9 Studies in rats 
showed that dietary protein via acid pro-
duction induces endothelin production. 8 
Endothelin stimulated collecting duct 
acid secretion via endothelin B receptors 
and tubulointerstitial injury via endothe-
lin A receptors 7,8 ( Figure 1 ). Bicarbonate 
ameliorated the injury induced by pro-
tein. 7 Wesson ’ s group further showed that 
dietary protein induced a lower cortical 
interstitial pH and, by manipulating the 
diet, showed that injury correlated with 
pH. 9 Other laboratories have demon-
strated that endothelin mediates in part 
the response of the proximal tubule to 
acidosis (see, for example, Laghmani 
 et al. 10 ). Clinical studies examining the 
mechanisms of the eff ects of correction 
of acidosis have been even more limited. 
Th us, the observation by Phisitkul  et al. 2 
(this issue) that sodium citrate may exert 
a beneficial effect on endothelin-
 mediated progression is important. Th e 
clinical studies by Phisitkul  et al. 2 also 
demonstrated a decrease in  N -acetyl-  -
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 D -glucosaminidase, a marker of tubu-
lointerstitial injury, urinary albumin, and 
urinary transforming growth factor-  1. 
Additional eff ects of bicarbonate or cit-
rate may yet be identifi ed. 
 The study by Phisitkul  et al. 2 also 
shows that over a 2-year period, treat-
ment with sodium citrate (equivalent to 
sodium bicarbonate but more palatable) 
slowed progression of CKD to severe 
CKD. (Th e eff ects on serum creatinine 
and estimated GFR were not statistically 
signifi cant with citrate therapy, but other 
measures of kidney disease progression 
were signifi cant.) Th is study addressed 
only patients with CKD presumably sec-
ondary to hypertension. A similar recent 
study in a larger group of patients with 
more varied etiology and more severe 
initial disease by de Brito-Ashurst  et al. 11 
showed a benefi cial eff ect of sodium bicar-
bonate on progression of CKD. Th e latter 
study also showed a benefi cial eff ect of 
sodium bicarbonate on nutritional param-
eters. Both recent clinical studies were 
remarkably similar in the eff ects of alkali 
treatment on progression of CKD. In both 
studies there was a group of control 
patients, representing 25 – 45 % of the con-
trols, who had a  dramatic decline in 
 kidney function over 12 – 30 months. In 
both studies, bicarbonate treatment 
decreased this number by about 80 % . 
Th us, this simple maneuver had powerful 
eff ects particularly in a subset of patients. 
 A potential concern regarding treat-
ment of patients with CKD with sodium 
bicarbonate or sodium citrate is the pos-
sible increase in extracellular fl uid volume 
and hypertension. Such concerns were 
addressed more than 30 years ago by Hus-
ted  et al. 12 Th ey examined patients with 
advanced CKD with average GFRs of 
about 10  ml / min. Patients were placed on 
an extremely low-sodium diet of 
10 mequiv. per day and supplemented 
with either sodium chloride or sodium 
bicarbonate. Sodium chloride but not 
sodium bicarbonate produced an increase 
in weight and blood pressure. Th e two 
recent clinical studies 2,11 suggest that 
sodium bicarbonate or citrate supplemen-
tation is indeed safe even when added to 
a more normal-sodium diet; blood pres-
sures, clinical edema, and heart failure 
were not worsened by sodium alkali sup-
plementation. Th e amount of sodium cit-
rate prescribed in the study by Phisitkul 
 et al. 2 was 1 mequiv. / kg / d. Th is amount of 
bicarbonate would be suffi  cient to neu-
tralize the entire acid load present in the 
usual Western diet. It seems likely that the 
amount of citrate ingested was less than 
prescribed (as judged by the reduction in 
net acid excretion). Th e amount of sodium 
bicarbonate used by Brito-Ashurst  et al. 11 
was 1800  mg in divided doses (about 21 
mequiv.), titrated up as needed to normal-
ize plasma bicarbonate; the amount actu-
ally used averaged 1820  mg / d. Thus, it 
appears that relatively modest doses of 
alkali are suffi  cient to exert a benefi cial 
eff ect. Th eoretical concerns about possible 
detrimental eff ects of alkali on calcium 
phosphate deposition in the kidney have 
not been borne out in these clinical stud-
ies. Another theoretical aspect that may 
not be clinically signifi cant, and which 
could be addressed in future studies, is 
that citrate (and not bicarbonate) has been 
shown to increase aluminum absorption 
in the gastrointestinal tract. 13 
 Th us, alkali supplementation as bicar-
bonate or citrate appears to be a promis-
ing and inexpensive approach to 
retarding progression of renal insuffi  -
ciency and improving nutritional status. 
Several unanswered questions remain. 
Will the results hold up to larger blinded 
studies in patients with diverse causes of 
kidney disease? What is the level of acido-
sis or plasma bicarbonate that  warrants 
treatment? If patients are not acidotic, will 
sodium bicarbonate or citrate be eff ective 
and safe? What amount of sodium bicarbo-
nate is actually needed to see the benefi cial 
eff ect? Finally, further studies on mecha-
nisms are needed. In the era of cost – benefi t 
analysis, alkali supplementation appears to 
be a promising low-cost, high-benefit 
adjunct treatment for patients with CKD. 
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 Figure 1  |  Mechanisms linking acidosis and CKD. CKD leads to metabolic acidosis, which may 
promote interstitial fibrosis due to adaptations in ammonia handling. Additionally, the acidic milieu 
may stimulate endothelin (ET) production, which may promote interstitial fibrosis. However, endothelin 
may have a salutatory effect of promoting acid secretion, which would ameliorate the acidosis (X). 
Bicarbonate therapy would directly ameliorate the acidosis (X). ETA, endothelin A; ETB, endothelin B. 
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 It is certain that a higher serum uric acid 
level increases the risk of gout. Many die-
tary factors raise the serum uric acid level, 
such as alcohol, seafood, and meat, whereas 
dairy intake reduces it. Th ere is now sub-
stantial evidence that higher  fructose 
intake also increases the serum uric acid 
level and increases the risk of gout. 1,2 How-
ever, it is unclear whether fructose, the 
predominant sweetener in sugar- sweetened 
beverages such as sodas, has other 
 important health consequences. 
 Much of the debate around the role of 
fructose involves the potential impact of 
serum uric acid on blood pressure. A 
higher serum uric acid level is associated 
with an increased risk of hypertension in 
younger individuals, but it is unclear 
whether the uric acid is causal or simply a 
marker. Th ere are persuasive animal data 
about the potential harmful eff ect of uric 
acid on vascular function and blood pres-
sure, but the importance in humans 
remains to be determined. In fact, several 
lines of evidence suggest that uric acid may 
be only a marker for hypertension risk in 
humans. For example, reducing uric acid 
levels in humans either with recombinant 
uricase or with probenecid does not 
improve vascular function, in contrast to 
animal studies. 3,4 Furthermore, the pros-
pective association between fructose 
 Sugar-sweetened beverages and 
chronic disease 
 Gary C.  Curhan 1 and  John P.  Forman 1 
 Sugar-sweetened beverages, a major source of fructose, raise serum uric 
acid levels and are associated with an increased risk of gout, hypertension, 
and diabetes.  However, it is unclear whether the associations with 
hypertension and diabetes are caused by fructose per se, or through some 
other mechanism.  Nevertheless, given their demonstrated adverse 
health associations and the lack of any health benefit, the evidence favors 
minimization of sugar-sweetened beverage intake. 
 Kidney International (2010)  77, 569 – 570.  doi: 10.1038/ki.2009.543 
 1 Channing Laboratory and Renal Division, 
Department of Medicine ,  Boston , 
 Massachusetts ,  USA  
  Correspondence: Gary C. Curhan, Channing 
Laboratory and Renal Division, Department 
of Medicine, 181 Longwood Avenue, Boston, 
Massachusetts 02115, USA. 
E-mail:  gcurhan@partners.org 
intake and gout and that between fructose 
intake and hypertension are greatly dis-
similar ( Figure 1 ). Th is was demonstrated 
by the strong association between fructose 
intake and risk of gout in a large male 
cohort. However, a prospective study in 
this same male cohort and two large female 
cohorts, involving more than 200,000 
individuals and over 57,000 incident cases 
of hypertension, found no association 
between fructose intake and risk of inci-
dent hypertension. 5 In addition, a signifi -
cant  associat ion b e t we en  s o d a 
consumption and hypertension was 
found for both sugar-sweetened and arti-
fi cially sweetened beverages, 6 suggesting 
a mechanism not related to the sweetener. 
Th us, at present, it does not seem likely 
that fructose intake infl uences the risk of 
hypertension in humans. 
 The inverse cross-sectional relation 
between serum uric acid and renal func-
tion has been known for decades, but 
recent studies also suggest that higher uric 
acid levels may predict the subsequent loss 
of renal function, though not necessarily 
with chronic kidney disease. 7 Although 
animal data suggest a potential causal rela-
tion, the human data to date support only 
a possible association. 
 Bomback and colleagues8 (this issue) 
now report on a study examining the rela-
tion between sugar-sweetened soda con-
sumption and hyperuricemia and chronic 
kidney disease (CKD). Th ey believed that 
hyperuricemia was  ‘ a causal intermediate 
in the association of sugar-sweetened soda 
consumption and CKD, ’ so they analyzed 
these outcomes separately. Th ey used the 
well-known and high-quality Atheroscle-
rosis Risk in Communities study (ARIC), 
involving more than 15,000 white and 
black adults in the United States. As 
expected, the baseline cross-sectional 
study found that individuals with higher 
sugar-sweetened soda consumption were 
signifi cantly more likely to meet the crite-
ria for hyperuricemia. Th e fi ndings are 
consistent with previous reports, including 
those from the National Health and Nutri-
tion Examination Survey (NHANES). 2 
Bomback  et al. 8 also found a marginal 
association between higher soda con-
sumption and prevalent CKD (estimated 
glomerular fi ltration rate   <  60  ml / min per 
1.73  m 2 ). However, in the longitudinal 
